Abstract
Abstract Introduction: Commonly used biomarkers to assess the cancer preventive activity of cancer preventive agents include markers of cell proliferation or apoptosis. However, the expression of proliferation or apoptosis markers is highly variable, and measurement is often done using semi-quantitative assays. In addition, cancer preventive agents may act through mechanisms that do not depend on proliferation or apoptosis. Therefore, identification of new biomarkers indicative of the cancer preventive activity of chemopreventive agents is essential for the development of new cancer preventive drugs. Methods: We applied high-content microscopic analysis to assess the phenotypic changes occurring in normal mammary epithelial cells (HMECs) after treatment with cancer preventive drugs by measuring cell proliferation, DNA and neutral lipid content and localization, as well as cell cycle distribution of the cells. Gene specific knock-down was achieved by transfections with siRNA duplexes. Measurement of transcript levels was performed using quantitative real-time RT-PCR. Results: Multiparametric analysis of high-throughput image based studies have revealed that anti-proliferative activity of cancer preventive rexinoids is associated with increased formation of cytoplasmic lipid droplets. Accumulation of cytoplasmic neutral lipids was restricted to cell types that undergo significant growth suppression by bexarotene (HMECs, SUM225, and ZR75.1), but not observed in retinoid-resistant cells (MCF10A, HCC1937, and HCC1143). Other growth suppressive drugs including the kinase inhibitor lapatinib, vitamin D, and certain natural compounds, including epicatechine monogallate, duartin, actinonin and homoisoflavonoids, were also found to increase cellular neutral lipid content in breast cells. The addition of external fatty acids, such as oleic and palmitoleic acids did not result in dose-dependent growth suppression or accumulation of neutral esterified lipid droplets. Lipid accumulation and growth suppression were associated with the up-regulation of genes involved in regulating the formation of neutral lipids, triglycerides and phospholipids, but not genes involved in de novo fatty acid synthesis. Conversely, knock-down of key proteins controlling cellular triglyceride synthesis and storage, diacylglycerol acyltransferase 1 (DGAT1) and adipophyllin (Adfp) increased cell proliferation whereas their induction was associated with growth suppression in HMECs. Conclusion: These results suggest that increased accumulation of cellular triglycerides may be a useful biomarker to assess the preventive effect of putative cancer preventive agents. These results support the systematic testing of cellular neutral lipid levels in preclinical and clinical models testing novel chemopreventive agents. This work was supported by the grant RO1 CA 78480 (to P.H.B.). Citation Information: Cancer Prev Res 2011;4(10 Suppl):B69.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
